Jingping Zhao

Second Xiangya Hospital of Central South University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Wenbin Guo

Second Xiangya Hospital of Central South University

Feng Liu

Tianjin Medical University General Hospital

Renrong Wu

Second Xiangya Hospital of Central South University

Jindong Chen

Second Xiangya Hospital of Central South University

Jianjun Ou

Second Xiangya Hospital of Central South University

Zhening Liu

Second Xiangya Hospital of Central South University

Xilong Cui

Fuyang City People's Hospital

Kun Xia

Central South University

Guangrong Xie

Second Xiangya Hospital of Central South University

Yangpan Ou

Second Xiangya Hospital of Central South University

Cooperative Institutions

Central South University

239

Second Xiangya Hospital of Central South University

159

Shanghai Jiao Tong University

110

Chinese Academy of Sciences

Sichuan University

Peking University

Sun Yat-sen University

Zhejiang University

Chinese Academy of Medical Sciences & Peking Union Medical College

Xiangya Hospital Central South University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Breaking the Fear Barrier: Aberrant Activity of Fear Networks as a Prognostic Biomarker in Patients with Panic Disorder Normalized by Pharmacotherapy

Biomedicines (2023)

Haohao Yan Yiding Han Xiaoxiao Shan Huabing Li Feng Liu

Panic disorder (PD) is a prevalent type of anxiety disorder. Previous studies have reported abnormal brain activity in the fear network of patients with PD. Nonetheless, it remains uncertain whether pharmacotherapy can effectively normalize these abnormalities. This longitudinal resting-state functional magnetic resonance imaging study aimed to investigate the spontaneous neural activity in patients with PD and its changes after pharmacotherapy, with a focus on determining whether it could predict treatment response. The study included 54 drug-naive patients with PD and 54 healthy controls (HCs). Spontaneous neural activity was measured using regional homogeneity (ReHo). Additionally, support vector regression (SVR) was employed to predict treatment response from ReHo. At baseline, PD patients had aberrant ReHo in the fear network compared to HCs. After 4 weeks of paroxetine treatment (20 mg/day), a significant increase in ReHo was observed in the left fusiform gyrus, which had shown reduced ReHo before treatment. The SVR analysis showed significantly positive correlations (p < 0.0001) between the predicted and actual reduction rates of the severity of anxiety and depressive symptoms. Here, we show patients with PD had abnormal spontaneous neural activities in the fear networks. Furthermore, these abnormal spontaneous neural activities can be partially normalized by pharmacotherapy and serve as candidate predictors of treatment response. Gaining insight into the trajectories of brain activity normalization following treatment holds the potential to provide vital insights for managing PD.

Pharmacotherapy

Paroxetine

10.3390/biomedicines11092420

Cite

Citations (2)

Case-control association study of ABCB1 gene and major depressive disorder in a local Chinese Han population

Neuropsychiatric Disease and Treatment (2015)

Weiwei Xie Lin Zhang Renrong Wu Yan Yu Jingping Zhao

Human P-glycoprotein encoded by the ATP-binding cassette sub-family B member 1 (ABCB1) gene is expressed in the blood-brain barrier. ABCB1 protects the brain from many drugs and toxins such as glucocorticoids through the efflux pump. Recent evidence suggests that a specific allele of the ABCB1 gene confers susceptibility to major depressive disorder (MDD) in the Japanese population. The aim of this study was to explore the association of ABCB1 gene polymorphisms with MDD in a local Chinese Han population.Two hundred and ninety-two MDD patients and 208 unrelated individuals were matched by age and sex and examined using a case-control design. Six single nucleotide polymorphisms (SNPs) of the ABCB1 gene, including rs1045642, rs2032583, rs2032582, rs2235040, rs1128503, and rs2235015, were genotyped by ligase detection reaction and multiplex polymerase chain reaction. Linkage disequilibrium and haplotype analysis were investigated in the two study groups.Significant protection for MDD individuals carrying the TG haplotype of rs1045642-rs2032582 was observed (odds ratio 0.470, 95% confidence interval 0.251-0.897, P=0.01). The rs2032582 (G2677T) and rs1128503 (C1236T) SNPs of ABCB1 showed nominal associations with MDD; the other four SNPs of the ABCB1 gene were not associated with MDD.Chinese individuals carrying the TG haplotype of rs1045642-rs2032582 had a nearly 53% lower risk of developing MDD. To the best of our knowledge, this is the first report to analyze the effect of ABCB1 polymorphism on the risk of MDD in a Chinese population.

Linkage Disequilibrium

10.2147/ndt.s87175

Cite

Citations (14)

Shuganjieyu capsule increases neurotrophic factor expression in a rat model of depression

Neural Regeneration Research (2014)

Jingping Zhao Yong Liu Jinhua Fu Yingjin Zhang Renrong Wu

Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Ad-ministration of China since 2008. In the clinic, Shuganjieyu capsule is often used to treat mild to moderate depression. In the rat model of depression established in this study, Shuganjieyu capsule was administered intragastrically daily before stress. Behavioral results confirmed that depressive symptoms lessened after treatment with high-dose (150 mg/kg) Shuganjieyu capsule. Immunohistochemistry results showed that high-dose Shuganjieyu capsule significantly increased phosphorylation levels of phosphorylation cyclic adenosine monophosphate response element binding protein and brain-derived neurotrophic factor expression in the medial prefrontal cortex and hippocampal CA3 area. Overall, our results suggest that in rats, Shuganjieyu capsule effec-tively reverses depressive-like behaviors by increasing expression levels of neurotrophic factors in the brain.

Capsule

Depression

Cyclic adenosine monophosphate

10.4103/1673-5374.130067

Cite

Citations (14)

Probiotic supplements reduce antipsychotic-induced metabolic disturbances in drug-naïve first-episode schizophrenia

medRxiv (Cold Spring Harbor Laboratory) (2021)

Dongyu Kang Fengyu Zhang Ye Yang Chenchen Liu Jingmei Xiao

ABSTRACT Probiotic supplements have demonstrated efficacy in improving metabolic abnormalities and may prevent antipsychotic-induced metabolic disturbance and weight gain. A few studies in rodents have found that antipsychotic-induced metabolic dysfunctions are associated with the altered composition of gut microbiota. Here, we conducted a randomized-controlled clinical trial to determine the effectiveness and safety of probiotic supplements on antipsychotic-induced metabolic disturbance and weight gain. Patients with drug-naïve first-episode schizophrenia were randomized to receive either olanzapine plus probiotics or olanzapine monotherapy and scheduled to evaluate with follow-ups for clinical and metabolic profiles. After a treatment of 12 weeks with addition of probiotics, the increase of mean fasting insulin was significantly lower than olanzapine monotherapy. Insulin resistance increased considerably in the olanzapine plus probiotics, but also significantly lower than olanzapine monotherapy. We noted a difference in the increase in body mass index and body weight between treatments at a nominal level of significance, but it became non-significant after adjusting for appetite increase. Probiotics concurrently used with olanzapine is effective and safe in attenuating antipsychotic-induced elevation of fasting insulin and insulin resistance, but not the weight gain in drug-naïve first-episode schizophrenia. Further study is warranted to assess the longer-term maintenance of efficacy and safety.

10.1101/2021.02.16.21251872

Cite

Citations (2)

The relationship between neurotrophins and bipolar disorder

Expert Review of Neurotherapeutics (2013)

Renrong Wu Jinbo Fan Jingping Zhao Joseph R. Calabrese Keming Gao

Relationship between neurotrophins, especially brain-derived neurotrophic factor (BDNF) and bipolar disorder (BPD) has been widely investigated, but results have been inconsistent. BDNF polymorphism may be associated with the susceptibility to subtype BPD such as rapid cycling BPD or early onset BPD. Met allele carriers of Val66Met of BDNF gene had smaller gray matter (GM) in both patients and healthy controls, but bipolar patients carrying Met allele had better response to lithium treatment. Decreased serum/plasma BDNF levels were observed at different mood states. BDNF may interact with other systems to execute its neuroprotective effects. Overall data suggest that neurotrophins may be involved in the pathogenesis of BPD and treatment response, but the magnitude of their role needs further investigation with large sample size studies.

10.1586/14737175.2014.863709

Cite

Citations (27)

Frequency-specific altered global signal topography in drug-naïve first-episode patients with adolescent-onset schizophrenia

Brain Imaging and Behavior (2020)

Xiao Wang Wei Liao Shaoqiang Han Jiao Li Yifeng Wang

Drug-naïve

10.1007/s11682-020-00381-9

Cite

Citations (9)

Effect of Citalopram on Hippocampal Atrophy in First-Episode Psychosis: Structural MRI Results From the DECIFER Trial

Biological Psychiatry (2020)

Wei Qi Chenxiang Li Esther Blessing Babak A. Ardekani Oliver Freudenreich

Citalopram

10.1016/j.biopsych.2020.02.439

Cite

Citations (0)

Disrupted asymmetry of inter- and intra-hemispheric functional connectivity in patients with drug-naive, first-episode schizophrenia and their unaffected siblings

EBioMedicine (2018)

Furong Zhu Feng Liu Wenbin Guo Jindong Chen Qinji Su

Postcentral gyrus

Angular gyrus

Middle temporal gyrus

10.1016/j.ebiom.2018.09.012

Cite

Citations (41)

Brain structural abnormalities as potential markers for detecting individuals with ultra-high risk for psychosis: A systematic review and meta-analysis

Schizophrenia Research (2019)

Yudan Ding Yangpan Ou Pan Pan Xiaoxiao Shan Jindong Chen

10.1016/j.schres.2019.05.015

Cite

Citations (123)

An evaluation of family burden and family function on major depression

Maosheng Fang Jingping Zhao

Objective To study the family burden and family function of major depression.Methods 150 major depressive patients who met with DSM-Ⅳ criteria were enrolled randomly and investigated.Family Burden Scale (FBS) was used to evaluate the family burden,Family APGAR Index(APGAR) was used to evaluate the family function of major depressive patients,comparing to the control group.Results Positive rate (the family proportion whose factor score no less the average score) in four factors of FBS such as family economic burden,family daily activities,family entertainment and mental health of family member were higher(57.1%,51.6%,61.9%,78.6%).In rural patients,the factor score of family economic burden was higher than that of urban patients(1.14±0.09 vs 0.89±0.07,t =2.687,P ＜0.05),and the factor score of mental health of family member was lower(0.42±0.36 vs 0.60±0.58,t =3.375,P ＜0.01).There was no significant difference between premorbid family dysfunction of major depression and control group(24.6% vs 17.3%;χ2＝0.108,P ＞0.05).Significant differences were found in family dysfunction not only between premorbid and postmorbid(63.4% vs 24.6%,χ2＝70.045,P ＜0.01)but also between postmorbid and control group( P ＜0.01).The total scores and each factor score of APGAR in postmorbid were lower than premorbid(all P ＜0.01).Conclusion The family burden and family dysfunction of major depression were serious and multiple,which must be payed close attention and give effective intervention. Key words: Burden of disease; Major depression; Family burden; Family function

Depression

Dysfunctional family

Family health

Family member

10.3760/cma.j.issn.1674-6554.2009.02.002

Cite

Citations (0)